Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-12-24Clinical Trial Update: A Safety Study of SEA-BCMA in Patients With Multiple Myeloma [Phase 1]
Phase 1 safety study of SEA-BCMA in patients with multiple myeloma was terminated. Results were posted on 2024-12-24.
-
CLINICAL_TRIALS research · 2024-12-20Clinical Trial Update: SIL as Maintenance Therapy in Multiple Myeloma [Phase 2]
Phase 2 clinical trial studying SIL as maintenance therapy for multiple myeloma; the study is currently not yet recruiting. Sponsor: Navy Ge…
-
CLINICAL_TRIALS research · 2024-12-20Clinical Trial Update: BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma [NA]
A clinical trial update indicates a BCMA/CD3 bispecific antibody is being studied for high-risk smoldering multiple myeloma, with the trial …
-
CLINICAL_TRIALS research · 2024-12-20Clinical Trial Update: A Cross-sectional Study on the Positive Rate of M Protein Based on a Highly Sensitive Serum M Protein Detection Method.
This clinical trial update reports a cross-sectional study assessing the positive rate of serum M protein using a highly sensitive detection…
-
CLINICAL_TRIALS research · 2024-12-19Clinical Trial Update: To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma [Phase 3]
Phase 3 trial evaluating QL2109 in combination with DARZALEX FASPRO for multiple myeloma is listed as not yet recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-12-19FDA Approved: CYCLOPHOSPHAMIDE — Original Application (BluePoint Laboratories)
FDA approved BluePoint Laboratories' original ANDA for cyclophosphamide, establishing a generic version of the chemotherapy agent.
-
CLINICAL_TRIALS research · 2024-12-18Clinical Trial Update: Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone [Phase 3]
A Phase 3 clinical trial evaluating a therapy for advanced relapsed/refractory multiple myeloma with vs without dexamethasone is currently r…
-
CLINICAL_TRIALS research · 2024-12-17Clinical Trial Update: Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma [EARLY_Phase 1]
A pilot early-phase 1 trial is investigating whether changes in serum BCMA can indicate disease progression in multiple myeloma and the stud…
-
CLINICAL_TRIALS research · 2024-12-17Clinical Trial Update: A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS [Phase 1]
A Phase 1 study of FD-001 in recurrent/refractory acute myeloid leukemia, non-Hodgkin lymphoma, multiple myeloma, and myelodysplastic syndro…
-
CLINICAL_TRIALS trial_result · 2024-12-13Clinical Trial Update: Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma [Phase 2]
Phase 2 trial evaluating dendritic cell therapy for acute myeloid leukemia, chronic myeloid leukemia, and multiple myeloma reports efficacy …
-
CLINICAL_TRIALS research · 2024-12-13Clinical Trial Update: A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma [EARLY_Phase 1]
This is an early-phase dose-escalation trial evaluating a CD19/CD22/BCMA CAR-T cell therapy for relapsed or refractory multiple myeloma; rec…
-
CLINICAL_TRIALS research · 2024-12-13Clinical Trial Update: A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea
This ClinicalTrials.gov update describes a long-term safety study of Abecma (idecabtagene vicleucel) in adults with newly diagnosed multiple…
-
CLINICAL_TRIALS research · 2024-12-13Clinical Trial Update: A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
A Phase 1/2 study of IBI3003 for relapsed or refractory multiple myeloma is currently recruiting, sponsored by Innovent Biologics (Suzhou) C…
-
CLINICAL_TRIALS research · 2024-12-12Clinical Trial Update: Patient and Care Partner Experiences Living With Multiple Myeloma (PaCE-MM)
This update notes that the PaCE-MM study on patient and care partner experiences living with multiple myeloma has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-12-12Clinical Trial Update: a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia [EARLY_Phase 1]
Early-phase 1 clinical trial of CT0596 for relapsed/refractory multiple myeloma and relapsed/refractory plasma cell leukemia is currently re…
-
CLINICAL_TRIALS research · 2024-12-11Clinical Trial Update: Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple Myeloma
A completed clinical trial (NCT03848676) investigates the genomic and phenotypic determinants of resistance to immunotherapies in patients w…
-
CLINICAL_TRIALS trial_result · 2024-12-11Clinical Trial Update: Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression
This clinical trial investigated the role of extracellular NAMPT (eNAMPT) in the biology and progression of multiple myeloma; the study has …
-
CLINICAL_TRIALS research · 2024-12-11Clinical Trial Update: Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab [NA]
A real-world study of relapsed/refractory multiple myeloma patients treated with isatuximab is currently recruiting, sponsored by Pack Healt…
-
CLINICAL_TRIALS research · 2024-12-11Clinical Trial Update: Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients [Phase 2, Phase 3]
An ongoing Phase 2/Phase 3 trial is evaluating expression-linked and R-ISS–adapted stratification to guide first-line therapy in newly diagn…
-
CLINICAL_TRIALS trial_result · 2024-12-10Clinical Trial Update: Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A) [Phase 2]
Phase 2 MATCH subprotocol evaluating afatinib for cancers with EGFR genetic alterations; results have been posted and the trial is active bu…
-
CLINICAL_TRIALS research · 2024-12-09Clinical Trial Update: The Unmet Needs of Cancer Survivors in Ausl IRCCS Reggio Emilia
A clinical trial update from the University of Modena and Reggio Emilia shows a recruiting study at Ausl IRCCS Reggio Emilia focused on unme…
-
CLINICAL_TRIALS research · 2024-12-06Clinical Trial Update: Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.
Clinical Trial Update discusses evaluating whether measurable residual disease (MRD) status predicts outcomes within a Phase III trial compa…
-
CLINICAL_TRIALS research · 2024-12-06Clinical Trial Update: Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma [Phase 3]
Phase 3 trial comparing continuous versus fixed-duration therapy with daratumumab, lenalidomide, and dexamethasone in relapsed multiple myel…
-
CLINICAL_TRIALS trial_result · 2024-12-06Clinical Trial Update: A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma [Phase 1]
Phase 1 clinical study of TQB2029 for injection in subjects with multiple myeloma is currently recruiting.
-
CLINICAL_TRIALS research · 2024-12-06Clinical Trial Update: Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Multiple Myeloma [Phase 2]
Phase 2 clinical trial of carfilzomib, cyclophosphamide, and dexamethasone with maintenance carfilzomib in multiple myeloma; the study statu…